Bezisterim

N/A

Report date: 2025/11/17 10:08:06
NME

Base Information

Drug NameBezisterim
Drug Alias Name17α-ethynyl-5-androstene-3β,7β,17β-triol3α-ethynyl-androst-5-ene-3β,7β,17β-triolTriolexHE-3286NE-3107
ClassificationSmall molecules > SteroidsNatural product/Extract
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsNuclear factor NF-kappa-B complex inhibitorsExtracellular-signal-regulated kinase 2 inhibitors +[7] 
TargetsExtracellular-signal-regulated kinase1Nuclear factor NF-kappa-B complexExtracellular-signal-regulated kinase 2 +[7] 
Therapy Area/IndicationsPost-Acute COVID-19 SyndromeInsulin ResistanceDiabetes Mellitus, Type 2 +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHarbor Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiovie Inc
Inactive CompaniesHarbor Therapeutics Inc
Active IndicationsPost-Acute COVID-19 SyndromeAlzheimer DiseaseParkinson Disease
Inactive IndicationsInsulin ResistanceDiabetes Mellitus, Type 2Brain Injuries, Traumatic +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBank